APO Research
Talk to an analyst

APO RESEARCH · REPORT

NK1/NK3 Receptor Antagonists

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global NK1/NK3 Receptor Antagonists Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

23 December 2025194 pages

Choose your research edition.

Industry ResearchNK1/NK3 Receptor Antagonists Industry Research Report 2026130 pages · $2,950 USDIndustry Growth & TrendsGlobal NK1/NK3 Receptor Antagonists Industry Growth and Trends Forecast to 2032112 pages · $3,450 USDMarket StructureGlobal NK1/NK3 Receptor Antagonists Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032194 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal NK1/NK3 Receptor Antagonists Market Outlook and Growth Opportunities 2026208 pages · $4,250 USDMarket Analysis & ForecastGlobal NK1/NK3 Receptor Antagonists Market Analysis and Forecast 2026-2032200 pages · $4,950 USD

Market perspective

The global NK1/NK3 Receptor Antagonists market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for NK1/NK3 Receptor Antagonists is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for NK1/NK3 Receptor Antagonists is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for NK1/NK3 Receptor Antagonists is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for NK1/NK3 Receptor Antagonists is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of NK1/NK3 Receptor Antagonists include Chia Tai Tianqing Pharmaceutical, Yichang Humanwell Pharmaceutical, Qilu Pharmaceutical, Merck, Luoxin Pharmaceutical, Jiangsu Hengrui Pharmaceuticals, Helsinn Healthcare, Hansoh Pharma and Fresenius Kabi, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global NK1/NK3 Receptor Antagonists market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of NK1/NK3 Receptor Antagonists and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents NK1/NK3 Receptor Antagonists sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the NK1/NK3 Receptor Antagonists market size, projected growth trends, production technologies, key applications, and end-use industries.

NK1/NK3 Receptor Antagonists Segment by Company

Chia Tai Tianqing Pharmaceutical

Yichang Humanwell Pharmaceutical

Qilu Pharmaceutical

Merck

Luoxin Pharmaceutical

Jiangsu Hengrui Pharmaceuticals

Helsinn Healthcare

Hansoh Pharma

Fresenius Kabi

Beijing Sihuan Pharmaceutical

Bayer

Astellas

Torrent Pharmaceuticals

TerSera Therapeutics

Heron Therapeutics

Glenmark

NK1/NK3 Receptor Antagonists Segment by Type

NK1 Receptor Antagonist

NK3 Receptor Antagonist

Dual Antagonist

NK1/NK3 Receptor Antagonists Segment by Application

Hospital

Specialty Clinic

NK1/NK3 Receptor Antagonists Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global NK1/NK3 Receptor Antagonists market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of NK1/NK3 Receptor Antagonists and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of NK1/NK3 Receptor Antagonists.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the NK1/NK3 Receptor Antagonists market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of NK1/NK3 Receptor Antagonists manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of NK1/NK3 Receptor Antagonists in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of NK1/NK3 Receptor Antagonists in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. NK1/NK3 Receptor Antagonists Industry Trends Table 2. NK1/NK3 Receptor Antagonists Industry Drivers Table 3. NK1/NK3 Receptor Antagonists Industry Opportunities and Challenges Table 4. NK1/NK3 Receptor Antagonists Industry Restraints Table 5. Global NK1/NK3 Receptor Antagonists Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global NK1/NK3 Receptor Antagonists Revenue Market Share by Manufacturers (2021-2026) Table 7. Global NK1/NK3 Receptor Antagonists Sales by Manufacturers (k units) & (2021-2026) Table 8. Global NK1/NK3 Receptor Antagonists Sales Market Share by Manufacturers Table 9. Global NK1/NK3 Receptor Antagonists Average Sales Price (USD/unit) of Manufacturers (2021-2026) Table 10. Global NK1/NK3 Receptor Antagonists Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global NK1/NK3 Receptor Antagonists Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global NK1/NK3 Receptor Antagonists Manufacturers, Product Type & Application Table 13. Global NK1/NK3 Receptor Antagonists Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global NK1/NK3 Receptor Antagonists by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of NK1 Receptor Antagonist Table 17. Major Manufacturers of NK3 Receptor Antagonist Table 18. Major Manufacturers of Dual Antagonist Table 19. Global NK1/NK3 Receptor Antagonists Sales by Type 2021 VS 2025 VS 2032 (k units) Table 20. Global NK1/NK3 Receptor Antagonists Sales by Type (2021-2026) & (k units) Table 21. Global NK1/NK3 Receptor Antagonists Sales by Type (2027-2032) & (k units) Table 22. Global NK1/NK3 Receptor Antagonists Sales Market Share by Type (2021-2026) Table 23. Global NK1/NK3 Receptor Antagonists Sales Market Share by Type (2027-2032) Table 24. Global NK1/NK3 Receptor Antagonists Revenue by Type 2021 VS 2025 VS 2032 (k units) Table 25. Global NK1/NK3 Receptor Antagonists Revenue by Type (2021-2026) & (k units) Table 26. Global NK1/NK3 Receptor Antagonists Revenue by Type (2027-2032) & (k units) Table 27. Global NK1/NK3 Receptor Antagonists Revenue Market Share by Type (2021-2026) Table 28. Global NK1/NK3 Receptor Antagonists Revenue Market Share by Type (2027-2032) Table 29. Major Manufacturers of Hospital Table 30. Major Manufacturers of Specialty Clinic Table 31. Global NK1/NK3 Receptor Antagonists Sales by Application 2021 VS 2025 VS 2032 (k units) Table 32. Global NK1/NK3 Receptor Antagonists Sales by Application (2021-2026) & (k units) Table 33. Global NK1/NK3 Receptor Antagonists Sales by Application (2027-2032) & (k units) Table 34. Global NK1/NK3 Receptor Antagonists Sales Market Share by Application (2021-2026) Table 35. Global NK1/NK3 Receptor Antagonists Sales Market Share by Application (2027-2032) Table 36. Global NK1/NK3 Receptor Antagonists Revenue by Application 2021 VS 2025 VS 2032 (k units) Table 37. Global NK1/NK3 Receptor Antagonists Revenue by Application (2021-2026) & (k units) Table 38. Global NK1/NK3 Receptor Antagonists Revenue by Application (2027-2032) & (k units) Table 39. Global NK1/NK3 Receptor Antagonists Revenue Market Share by Application (2021-2026) Table 40. Global NK1/NK3 Receptor Antagonists Revenue Market Share by Application (2027-2032) Table 41. Global NK1/NK3 Receptor Antagonists Sales by Region: 2021 VS 2025 VS 2032 (k units) Table 42. Global NK1/NK3 Receptor Antagonists Sales by Region (2021-2026) & (k units) Table 43. Global NK1/NK3 Receptor Antagonists Sales Market Share by Region (2021-2026) Table 44. Global NK1/NK3 Receptor Antagonists Sales Forecasted by Region (2027-2032) & (k units) Table 45. Global NK1/NK3 Receptor Antagonists Sales Forecasted Market Share by Region (2027-2032) Table 46. North America NK1/NK3 Receptor Antagonists Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 47. North America NK1/NK3 Receptor Antagonists Sales by Country (2021-2026) & (k units) Table 48. North America NK1/NK3 Receptor Antagonists Sales by Country (2027-2032) & (k units) Table 49. Europe NK1/NK3 Receptor Antagonists Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 50. Europe NK1/NK3 Receptor Antagonists Sales by Country (2021-2026) & (k units) Table 51. Europe NK1/NK3 Receptor Antagonists Sales by Country (2027-2032) & (k units) Table 52. Asia Pacific NK1/NK3 Receptor Antagonists Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 53. Asia Pacific NK1/NK3 Receptor Antagonists Sales by Country (2021-2026) & (k units) Table 54. Asia Pacific NK1/NK3 Receptor Antagonists Sales by Country (2027-2032) & (k units) Table 55. South America, Middle East and Africa NK1/NK3 Receptor Antagonists Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 56. South America, Middle East and Africa NK1/NK3 Receptor Antagonists Sales by Country (2021-2026) & (k units) Table 57. South America, Middle East and Africa NK1/NK3 Receptor Antagonists Sales by Country (2027-2032) & (k units) Table 58. Global NK1/NK3 Receptor Antagonists Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 59. Global NK1/NK3 Receptor Antagonists Revenue by Region (2021-2026) & (US$ Million) Table 60. Global NK1/NK3 Receptor Antagonists Revenue by Region (2027-2032) & (US$ Million) Table 61. Global NK1/NK3 Receptor Antagonists Revenue Market Share by Region (2021-2026) Table 62. Global NK1/NK3 Receptor Antagonists Revenue Market Share by Region (2027-2032) Table 63. Chia Tai Tianqing Pharmaceutical Company Information Table 64. Chia Tai Tianqing Pharmaceutical Business Overview Table 65. Chia Tai Tianqing Pharmaceutical NK1/NK3 Receptor Antagonists Sales (k units), Price (USD/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 66. Chia Tai Tianqing Pharmaceutical NK1/NK3 Receptor Antagonists Product Portfolio Table 67. Chia Tai Tianqing Pharmaceutical Recent Development Table 68. Yichang Humanwell Pharmaceutical Company Information Table 69. Yichang Humanwell Pharmaceutical Business Overview Table 70. Yichang Humanwell Pharmaceutical NK1/NK3 Receptor Antagonists Sales (k units), Price (USD/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 71. Yichang Humanwell Pharmaceutical NK1/NK3 Receptor Antagonists Product Portfolio Table 72. Yichang Humanwell Pharmaceutical Recent Development Table 73. Qilu Pharmaceutical Company Information Table 74. Qilu Pharmaceutical Business Overview Table 75. Qilu Pharmaceutical NK1/NK3 Receptor Antagonists Sales (k units), Price (USD/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 76. Qilu Pharmaceutical NK1/NK3 Receptor Antagonists Product Portfolio Table 77. Qilu Pharmaceutical Recent Development Table 78. Merck Company Information Table 79. Merck Business Overview Table 80. Merck NK1/NK3 Receptor Antagonists Sales (k units), Price (USD/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 81. Merck NK1/NK3 Receptor Antagonists Product Portfolio Table 82. Merck Recent Development Table 83. Luoxin Pharmaceutical Company Information Table 84. Luoxin Pharmaceutical Business Overview Table 85. Luoxin Pharmaceutical NK1/NK3 Receptor Antagonists Sales (k units), Price (USD/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 86. Luoxin Pharmaceutical NK1/NK3 Receptor Antagonists Product Portfolio Table 87. Luoxin Pharmaceutical Recent Development Table 88. Jiangsu Hengrui Pharmaceuticals Company Information Table 89. Jiangsu Hengrui Pharmaceuticals Business Overview Table 90. Jiangsu Hengrui Pharmaceuticals NK1/NK3 Receptor Antagonists Sales (k units), Price (USD/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 91. Jiangsu Hengrui Pharmaceuticals NK1/NK3 Receptor Antagonists Product Portfolio Table 92. Jiangsu Hengrui Pharmaceuticals Recent Development Table 93. Helsinn Healthcare Company Information Table 94. Helsinn Healthcare Business Overview Table 95. Helsinn Healthcare NK1/NK3 Receptor Antagonists Sales (k units), Price (USD/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 96. Helsinn Healthcare NK1/NK3 Receptor Antagonists Product Portfolio Table 97. Helsinn Healthcare Recent Development Table 98. Hansoh Pharma Company Information Table 99. Hansoh Pharma Business Overview Table 100. Hansoh Pharma NK1/NK3 Receptor Antagonists Sales (k units), Price (USD/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 101. Hansoh Pharma NK1/NK3 Receptor Antagonists Product Portfolio Table 102. Hansoh Pharma Recent Development Table 103. Fresenius Kabi Company Information Table 104. Fresenius Kabi Business Overview Table 105. Fresenius Kabi NK1/NK3 Receptor Antagonists Sales (k units), Price (USD/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 106. Fresenius Kabi NK1/NK3 Receptor Antagonists Product Portfolio Table 107. Fresenius Kabi Recent Development Table 108. Beijing Sihuan Pharmaceutical Company Information Table 109. Beijing Sihuan Pharmaceutical Business Overview Table 110. Beijing Sihuan Pharmaceutical NK1/NK3 Receptor Antagonists Sales (k units), Price (USD/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 111. Beijing Sihuan Pharmaceutical NK1/NK3 Receptor Antagonists Product Portfolio Table 112. Beijing Sihuan Pharmaceutical Recent Development Table 113. Bayer Company Information Table 114. Bayer Business Overview Table 115. Bayer NK1/NK3 Receptor Antagonists Sales (k units), Price (USD/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 116. Bayer NK1/NK3 Receptor Antagonists Product Portfolio Table 117. Bayer Recent Development Table 118. Astellas Company Information Table 119. Astellas Business Overview Table 120. Astellas NK1/NK3 Receptor Antagonists Sales (k units), Price (USD/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 121. Astellas NK1/NK3 Receptor Antagonists Product Portfolio Table 122. Astellas Recent Development Table 123. Torrent Pharmaceuticals Company Information Table 124. Torrent Pharmaceuticals Business Overview Table 125. Torrent Pharmaceuticals NK1/NK3 Receptor Antagonists Sales (k units), Price (USD/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 126. Torrent Pharmaceuticals NK1/NK3 Receptor Antagonists Product Portfolio Table 127. Torrent Pharmaceuticals Recent Development Table 128. TerSera Therapeutics Company Information Table 129. TerSera Therapeutics Business Overview Table 130. TerSera Therapeutics NK1/NK3 Receptor Antagonists Sales (k units), Price (USD/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 131. TerSera Therapeutics NK1/NK3 Receptor Antagonists Product Portfolio Table 132. TerSera Therapeutics Recent Development Table 133. Heron Therapeutics Company Information Table 134. Heron Therapeutics Business Overview Table 135. Heron Therapeutics NK1/NK3 Receptor Antagonists Sales (k units), Price (USD/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 136. Heron Therapeutics NK1/NK3 Receptor Antagonists Product Portfolio Table 137. Heron Therapeutics Recent Development Table 138. Glenmark Company Information Table 139. Glenmark Business Overview Table 140. Glenmark NK1/NK3 Receptor Antagonists Sales (k units), Price (USD/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 141. Glenmark NK1/NK3 Receptor Antagonists Product Portfolio Table 142. Glenmark Recent Development Table 143. Key Raw Materials Table 144. Raw Materials Key Suppliers Table 145. NK1/NK3 Receptor Antagonists Distributors List Table 146. NK1/NK3 Receptor Antagonists Customers List Table 147. Research Programs/Design for This Report Table 148. Authors List of This Report Table 149. Secondary Sources Table 150. Primary Sources List of Figures Figure 1. NK1/NK3 Receptor Antagonists Product Image Figure 2. Global NK1/NK3 Receptor Antagonists Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global NK1/NK3 Receptor Antagonists Market Size (2021-2032) & (US$ Million) Figure 4. Global NK1/NK3 Receptor Antagonists Sales (2021-2032) & (k units) Figure 5. Global NK1/NK3 Receptor Antagonists Average Price (USD/unit) & (2021-2032) Figure 6. Global Top 5 and 10 NK1/NK3 Receptor Antagonists Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. NK1 Receptor Antagonist Image Figure 9. NK3 Receptor Antagonist Image Figure 10. Dual Antagonist Image Figure 11. Global NK1/NK3 Receptor Antagonists Sales by Type (2021 VS 2025 VS 2032) & (k units) Figure 12. Global NK1/NK3 Receptor Antagonists Sales Market Share 2021 VS 2025 VS 2032 Figure 13. Global NK1/NK3 Receptor Antagonists Sales Market Share by Type (2021-2032) Figure 14. Global NK1/NK3 Receptor Antagonists Revenue by Type (2021 VS 2025 VS 2032) & (k units) Figure 15. Global NK1/NK3 Receptor Antagonists Revenue Market Share 2021 VS 2025 VS 2032 Figure 16. Global NK1/NK3 Receptor Antagonists Revenue Market Share by Type (2021-2032) Figure 17. Hospital Image Figure 18. Specialty Clinic Image Figure 19. Global NK1/NK3 Receptor Antagonists Sales by Application (2021 VS 2025 VS 2032) & (k units) Figure 20. Global NK1/NK3 Receptor Antagonists Sales Market Share 2021 VS 2025 VS 2032 Figure 21. Global NK1/NK3 Receptor Antagonists Sales Market Share by Application (2021-2032) Figure 22. Global NK1/NK3 Receptor Antagonists Revenue by Application (2021 VS 2025 VS 2032) & (k units) Figure 23. Global NK1/NK3 Receptor Antagonists Revenue Market Share 2021 VS 2025 VS 2032 Figure 24. Global NK1/NK3 Receptor Antagonists Revenue Market Share by Application (2021-2032) Figure 25. North America NK1/NK3 Receptor Antagonists Sales and Growth Rate (2021-2032) & (k units) Figure 26. North America NK1/NK3 Receptor Antagonists Sales Market Share by Country (2021-2032) Figure 27. U.S. NK1/NK3 Receptor Antagonists Sales and Growth Rate (2021-2032) & (k units) Figure 28. Canada NK1/NK3 Receptor Antagonists Sales and Growth Rate (2021-2032) & (k units) Figure 29. Mexico NK1/NK3 Receptor Antagonists Sales and Growth Rate (2021-2032) & (k units) Figure 30. Europe NK1/NK3 Receptor Antagonists Sales and Growth Rate (2021-2032) & (k units) Figure 31. Europe NK1/NK3 Receptor Antagonists Sales Market Share by Country (2021-2032) Figure 32. Germany NK1/NK3 Receptor Antagonists Sales and Growth Rate (2021-2032) & (k units) Figure 33. France NK1/NK3 Receptor Antagonists Sales and Growth Rate (2021-2032) & (k units) Figure 34. U.K. NK1/NK3 Receptor Antagonists Sales and Growth Rate (2021-2032) & (k units) Figure 35. Italy NK1/NK3 Receptor Antagonists Sales and Growth Rate (2021-2032) & (k units) Figure 36. Netherlands NK1/NK3 Receptor Antagonists Sales and Growth Rate (2021-2032) & (k units) Figure 37. Asia Pacific NK1/NK3 Receptor Antagonists Sales and Growth Rate (2021-2032) & (k units) Figure 38. Asia Pacific NK1/NK3 Receptor Antagonists Sales Market Share by Country (2021-2032) Figure 39. China NK1/NK3 Receptor Antagonists Sales and Growth Rate (2021-2032) & (k units) Figure 40. Japan NK1/NK3 Receptor Antagonists Sales and Growth Rate (2021-2032) & (k units) Figure 41. South Korea NK1/NK3 Receptor Antagonists Sales and Growth Rate (2021-2032) & (k units) Figure 42. Southeast Asia NK1/NK3 Receptor Antagonists Sales and Growth Rate (2021-2032) & (k units) Figure 43. India NK1/NK3 Receptor Antagonists Sales and Growth Rate (2021-2032) & (k units) Figure 44. Australia NK1/NK3 Receptor Antagonists Sales and Growth Rate (2021-2032) & (k units) Figure 45. South America, Middle East and Africa NK1/NK3 Receptor Antagonists Sales and Growth Rate (2021-2032) & (k units) Figure 46. South America, Middle East and Africa NK1/NK3 Receptor Antagonists Sales Market Share by Country (2021-2032) Figure 47. Brazil NK1/NK3 Receptor Antagonists Sales and Growth Rate (2021-2032) & (k units) Figure 48. South Africa NK1/NK3 Receptor Antagonists Sales and Growth Rate (2021-2032) & (k units) Figure 49. Saudi Arabia NK1/NK3 Receptor Antagonists Sales and Growth Rate (2021-2032) & (k units) Figure 50. Turkey NK1/NK3 Receptor Antagonists Sales and Growth Rate (2021-2032) & (k units) Figure 51. Argentina NK1/NK3 Receptor Antagonists Sales and Growth Rate (2021-2032) & (k units) Figure 52. UAE NK1/NK3 Receptor Antagonists Sales and Growth Rate (2021-2032) & (k units) Figure 53. Egypt NK1/NK3 Receptor Antagonists Sales and Growth Rate (2021-2032) & (k units) Figure 54. Chile NK1/NK3 Receptor Antagonists Sales and Growth Rate (2021-2032) & (k units) Figure 55. Global NK1/NK3 Receptor Antagonists Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 56. Global NK1/NK3 Receptor Antagonists Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 57. North America NK1/NK3 Receptor Antagonists Revenue (2021-2032) & (US$ Million) Figure 58. North America NK1/NK3 Receptor Antagonists Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 59. Europe NK1/NK3 Receptor Antagonists Revenue (2021-2032) & (US$ Million) Figure 60. Europe NK1/NK3 Receptor Antagonists Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 61. Asia-Pacific NK1/NK3 Receptor Antagonists Revenue (2021-2032) & (US$ Million) Figure 62. Asia-Pacific NK1/NK3 Receptor Antagonists Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 63. South America, Middle East and Africa NK1/NK3 Receptor Antagonists Revenue (2021-2032) & (US$ Million) Figure 64. South America, Middle East and Africa NK1/NK3 Receptor Antagonists Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 65. NK1/NK3 Receptor Antagonists Value Chain Figure 66. Manufacturing Cost Structure Figure 67. NK1/NK3 Receptor Antagonists Production Mode & Process Figure 68. Direct Comparison with Distribution Share Figure 69. Distributors Profiles Figure 70. Years Considered Figure 71. Research Process Figure 72. Key Executives Interviewed

Scope & coverage.

Types
  • NK1 Receptor Antagonist
  • NK3 Receptor Antagonist
  • Dual Antagonist
Applications
  • Hospital
  • Specialty Clinic
Companies covered
  • Chia Tai Tianqing Pharmaceutical
  • Yichang Humanwell Pharmaceutical
  • Qilu Pharmaceutical
  • Merck
  • Luoxin Pharmaceutical
  • Jiangsu Hengrui Pharmaceuticals
  • Helsinn Healthcare
  • Hansoh Pharma
  • Fresenius Kabi
  • Beijing Sihuan Pharmaceutical
  • Bayer
  • Astellas
  • Torrent Pharmaceuticals
  • TerSera Therapeutics
  • Heron Therapeutics
  • Glenmark

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global NK1/NK3 Receptor Antagonists Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global NK1/NK3 Receptor Antagonists Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global NK1/NK3 Receptor Antagonists Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global NK1/NK3 Receptor Antagonists Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global NK1/NK3 Receptor Antagonists Market Dynamics
  1. 2.1 NK1/NK3 Receptor Antagonists Industry Trends
  2. 2.2 NK1/NK3 Receptor Antagonists Industry Drivers
  3. 2.3 NK1/NK3 Receptor Antagonists Industry Opportunities and Challenges
  4. 2.4 NK1/NK3 Receptor Antagonists Industry Restraints
3 NK1/NK3 Receptor Antagonists Market by Manufacturers
  1. 3.1 Global NK1/NK3 Receptor Antagonists Revenue by Manufacturers (2021-2026)
  2. 3.2 Global NK1/NK3 Receptor Antagonists Sales by Manufacturers (2021-2026)
  3. 3.3 Global NK1/NK3 Receptor Antagonists Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global NK1/NK3 Receptor Antagonists Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global NK1/NK3 Receptor Antagonists Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global NK1/NK3 Receptor Antagonists Manufacturers, Product Type & Application
  7. 3.7 Global NK1/NK3 Receptor Antagonists Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global NK1/NK3 Receptor Antagonists Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 NK1/NK3 Receptor Antagonists Players Market Share by Revenue in 2025
  11. 3.8.3 2025 NK1/NK3 Receptor Antagonists Tier 1, Tier 2, and Tier 3
4 NK1/NK3 Receptor Antagonists Market by Type
  1. 4.1 NK1/NK3 Receptor Antagonists Type Introduction
  2. 4.1.1 NK1 Receptor Antagonist
  3. 4.1.2 NK3 Receptor Antagonist
  4. 4.1.3 Dual Antagonist
  5. 4.2 Global NK1/NK3 Receptor Antagonists Sales by Type
  6. 4.2.1 Global NK1/NK3 Receptor Antagonists Sales by Type (2021 VS 2025 VS 2032)
  7. 4.2.2 Global NK1/NK3 Receptor Antagonists Sales by Type (2021-2032)
  8. 4.2.3 Global NK1/NK3 Receptor Antagonists Sales Market Share by Type (2021-2032)
  9. 4.3 Global NK1/NK3 Receptor Antagonists Revenue by Type
  10. 4.3.1 Global NK1/NK3 Receptor Antagonists Revenue by Type (2021 VS 2025 VS 2032)
  11. 4.3.2 Global NK1/NK3 Receptor Antagonists Revenue by Type (2021-2032)
  12. 4.3.3 Global NK1/NK3 Receptor Antagonists Revenue Market Share by Type (2021-2032)
5 NK1/NK3 Receptor Antagonists Market by Application
  1. 5.1 NK1/NK3 Receptor Antagonists Application Introduction
  2. 5.1.1 Hospital
  3. 5.1.2 Specialty Clinic
  4. 5.2 Global NK1/NK3 Receptor Antagonists Sales by Application
  5. 5.2.1 Global NK1/NK3 Receptor Antagonists Sales by Application (2021 VS 2025 VS 2032)
  6. 5.2.2 Global NK1/NK3 Receptor Antagonists Sales by Application (2021-2032)
  7. 5.2.3 Global NK1/NK3 Receptor Antagonists Sales Market Share by Application (2021-2032)
  8. 5.3 Global NK1/NK3 Receptor Antagonists Revenue by Application
  9. 5.3.1 Global NK1/NK3 Receptor Antagonists Revenue by Application (2021 VS 2025 VS 2032)
  10. 5.3.2 Global NK1/NK3 Receptor Antagonists Revenue by Application (2021-2032)
  11. 5.3.3 Global NK1/NK3 Receptor Antagonists Revenue Market Share by Application (2021-2032)
6 Global NK1/NK3 Receptor Antagonists Sales by Region
  1. 6.1 Global NK1/NK3 Receptor Antagonists Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global NK1/NK3 Receptor Antagonists Sales by Region (2021-2032)
  3. 6.2.1 Global NK1/NK3 Receptor Antagonists Sales by Region (2021-2026)
  4. 6.2.2 Global NK1/NK3 Receptor Antagonists Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America NK1/NK3 Receptor Antagonists Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America NK1/NK3 Receptor Antagonists Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe NK1/NK3 Receptor Antagonists Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe NK1/NK3 Receptor Antagonists Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific NK1/NK3 Receptor Antagonists Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific NK1/NK3 Receptor Antagonists Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa NK1/NK3 Receptor Antagonists Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa NK1/NK3 Receptor Antagonists Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global NK1/NK3 Receptor Antagonists Revenue by Region
  1. 7.1 Global NK1/NK3 Receptor Antagonists Revenue by Region
  2. 7.1.1 Global NK1/NK3 Receptor Antagonists Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global NK1/NK3 Receptor Antagonists Revenue by Region (2021-2026)
  4. 7.1.3 Global NK1/NK3 Receptor Antagonists Revenue by Region (2027-2032)
  5. 7.1.4 Global NK1/NK3 Receptor Antagonists Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America NK1/NK3 Receptor Antagonists Revenue (2021-2032)
  8. 7.2.2 North America NK1/NK3 Receptor Antagonists Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe NK1/NK3 Receptor Antagonists Revenue (2021-2032)
  11. 7.3.2 Europe NK1/NK3 Receptor Antagonists Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific NK1/NK3 Receptor Antagonists Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific NK1/NK3 Receptor Antagonists Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa NK1/NK3 Receptor Antagonists Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa NK1/NK3 Receptor Antagonists Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 Chia Tai Tianqing Pharmaceutical
  2. 8.1.1 Chia Tai Tianqing Pharmaceutical Company Information
  3. 8.1.2 Chia Tai Tianqing Pharmaceutical Business Overview
  4. 8.1.3 Chia Tai Tianqing Pharmaceutical NK1/NK3 Receptor Antagonists Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Chia Tai Tianqing Pharmaceutical NK1/NK3 Receptor Antagonists Product Portfolio
  6. 8.1.5 Chia Tai Tianqing Pharmaceutical Recent Developments
  7. 8.2 Yichang Humanwell Pharmaceutical
  8. 8.2.1 Yichang Humanwell Pharmaceutical Company Information
  9. 8.2.2 Yichang Humanwell Pharmaceutical Business Overview
  10. 8.2.3 Yichang Humanwell Pharmaceutical NK1/NK3 Receptor Antagonists Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Yichang Humanwell Pharmaceutical NK1/NK3 Receptor Antagonists Product Portfolio
  12. 8.2.5 Yichang Humanwell Pharmaceutical Recent Developments
  13. 8.3 Qilu Pharmaceutical
  14. 8.3.1 Qilu Pharmaceutical Company Information
  15. 8.3.2 Qilu Pharmaceutical Business Overview
  16. 8.3.3 Qilu Pharmaceutical NK1/NK3 Receptor Antagonists Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Qilu Pharmaceutical NK1/NK3 Receptor Antagonists Product Portfolio
  18. 8.3.5 Qilu Pharmaceutical Recent Developments
  19. 8.4 Merck
  20. 8.4.1 Merck Company Information
  21. 8.4.2 Merck Business Overview
  22. 8.4.3 Merck NK1/NK3 Receptor Antagonists Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Merck NK1/NK3 Receptor Antagonists Product Portfolio
  24. 8.4.5 Merck Recent Developments
  25. 8.5 Luoxin Pharmaceutical
  26. 8.5.1 Luoxin Pharmaceutical Company Information
  27. 8.5.2 Luoxin Pharmaceutical Business Overview
  28. 8.5.3 Luoxin Pharmaceutical NK1/NK3 Receptor Antagonists Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Luoxin Pharmaceutical NK1/NK3 Receptor Antagonists Product Portfolio
  30. 8.5.5 Luoxin Pharmaceutical Recent Developments
  31. 8.6 Jiangsu Hengrui Pharmaceuticals
  32. 8.6.1 Jiangsu Hengrui Pharmaceuticals Company Information
  33. 8.6.2 Jiangsu Hengrui Pharmaceuticals Business Overview
  34. 8.6.3 Jiangsu Hengrui Pharmaceuticals NK1/NK3 Receptor Antagonists Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Jiangsu Hengrui Pharmaceuticals NK1/NK3 Receptor Antagonists Product Portfolio
  36. 8.6.5 Jiangsu Hengrui Pharmaceuticals Recent Developments
  37. 8.7 Helsinn Healthcare
  38. 8.7.1 Helsinn Healthcare Company Information
  39. 8.7.2 Helsinn Healthcare Business Overview
  40. 8.7.3 Helsinn Healthcare NK1/NK3 Receptor Antagonists Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Helsinn Healthcare NK1/NK3 Receptor Antagonists Product Portfolio
  42. 8.7.5 Helsinn Healthcare Recent Developments
  43. 8.8 Hansoh Pharma
  44. 8.8.1 Hansoh Pharma Company Information
  45. 8.8.2 Hansoh Pharma Business Overview
  46. 8.8.3 Hansoh Pharma NK1/NK3 Receptor Antagonists Sales, Price, Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Hansoh Pharma NK1/NK3 Receptor Antagonists Product Portfolio
  48. 8.8.5 Hansoh Pharma Recent Developments
  49. 8.9 Fresenius Kabi
  50. 8.9.1 Fresenius Kabi Company Information
  51. 8.9.2 Fresenius Kabi Business Overview
  52. 8.9.3 Fresenius Kabi NK1/NK3 Receptor Antagonists Sales, Price, Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Fresenius Kabi NK1/NK3 Receptor Antagonists Product Portfolio
  54. 8.9.5 Fresenius Kabi Recent Developments
  55. 8.10 Beijing Sihuan Pharmaceutical
  56. 8.10.1 Beijing Sihuan Pharmaceutical Company Information
  57. 8.10.2 Beijing Sihuan Pharmaceutical Business Overview
  58. 8.10.3 Beijing Sihuan Pharmaceutical NK1/NK3 Receptor Antagonists Sales, Price, Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Beijing Sihuan Pharmaceutical NK1/NK3 Receptor Antagonists Product Portfolio
  60. 8.10.5 Beijing Sihuan Pharmaceutical Recent Developments
  61. 8.11 Bayer
  62. 8.11.1 Bayer Company Information
  63. 8.11.2 Bayer Business Overview
  64. 8.11.3 Bayer NK1/NK3 Receptor Antagonists Sales, Price, Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Bayer NK1/NK3 Receptor Antagonists Product Portfolio
  66. 8.11.5 Bayer Recent Developments
  67. 8.12 Astellas
  68. 8.12.1 Astellas Company Information
  69. 8.12.2 Astellas Business Overview
  70. 8.12.3 Astellas NK1/NK3 Receptor Antagonists Sales, Price, Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Astellas NK1/NK3 Receptor Antagonists Product Portfolio
  72. 8.12.5 Astellas Recent Developments
  73. 8.13 Torrent Pharmaceuticals
  74. 8.13.1 Torrent Pharmaceuticals Company Information
  75. 8.13.2 Torrent Pharmaceuticals Business Overview
  76. 8.13.3 Torrent Pharmaceuticals NK1/NK3 Receptor Antagonists Sales, Price, Revenue and Gross Margin (2021-2026)
  77. 8.13.4 Torrent Pharmaceuticals NK1/NK3 Receptor Antagonists Product Portfolio
  78. 8.13.5 Torrent Pharmaceuticals Recent Developments
  79. 8.14 TerSera Therapeutics
  80. 8.14.1 TerSera Therapeutics Company Information
  81. 8.14.2 TerSera Therapeutics Business Overview
  82. 8.14.3 TerSera Therapeutics NK1/NK3 Receptor Antagonists Sales, Price, Revenue and Gross Margin (2021-2026)
  83. 8.14.4 TerSera Therapeutics NK1/NK3 Receptor Antagonists Product Portfolio
  84. 8.14.5 TerSera Therapeutics Recent Developments
  85. 8.15 Heron Therapeutics
  86. 8.15.1 Heron Therapeutics Company Information
  87. 8.15.2 Heron Therapeutics Business Overview
  88. 8.15.3 Heron Therapeutics NK1/NK3 Receptor Antagonists Sales, Price, Revenue and Gross Margin (2021-2026)
  89. 8.15.4 Heron Therapeutics NK1/NK3 Receptor Antagonists Product Portfolio
  90. 8.15.5 Heron Therapeutics Recent Developments
  91. 8.16 Glenmark
  92. 8.16.1 Glenmark Company Information
  93. 8.16.2 Glenmark Business Overview
  94. 8.16.3 Glenmark NK1/NK3 Receptor Antagonists Sales, Price, Revenue and Gross Margin (2021-2026)
  95. 8.16.4 Glenmark NK1/NK3 Receptor Antagonists Product Portfolio
  96. 8.16.5 Glenmark Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 NK1/NK3 Receptor Antagonists Value Chain Analysis
  2. 9.1.1 NK1/NK3 Receptor Antagonists Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 NK1/NK3 Receptor Antagonists Production Mode & Process
  6. 9.2 NK1/NK3 Receptor Antagonists Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 NK1/NK3 Receptor Antagonists Distributors
  9. 9.2.3 NK1/NK3 Receptor Antagonists Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst